Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction

OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant statu...

Descripción completa

Detalles Bibliográficos
Autores principales: Savas, Murat, Yeni, Ercan, Verit, Ayhan, Gulum, Mehmet, Aksoy, Nurten, Ciftci, Halil, Celik, Hakim, Altunkol, Adem, Oncel, Halil
Formato: Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020342/
https://www.ncbi.nlm.nih.gov/pubmed/21340220
http://dx.doi.org/10.1590/S1807-59322010001200014
_version_ 1782196295836893184
author Savas, Murat
Yeni, Ercan
Verit, Ayhan
Gulum, Mehmet
Aksoy, Nurten
Ciftci, Halil
Celik, Hakim
Altunkol, Adem
Oncel, Halil
author_facet Savas, Murat
Yeni, Ercan
Verit, Ayhan
Gulum, Mehmet
Aksoy, Nurten
Ciftci, Halil
Celik, Hakim
Altunkol, Adem
Oncel, Halil
author_sort Savas, Murat
collection PubMed
description OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1±0.0 vs. 1.6±0.0 µmol H(2)O(2) Eq/L, 10.3±1.1 vs. 6.9±1.2 µmol H(2)O(2) Eq/L, and 236.4±19.5 vs. 228.2±19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.
format Text
id pubmed-3020342
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-30203422011-01-16 Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction Savas, Murat Yeni, Ercan Verit, Ayhan Gulum, Mehmet Aksoy, Nurten Ciftci, Halil Celik, Hakim Altunkol, Adem Oncel, Halil Clinics (Sao Paulo) Clinical Science OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1±0.0 vs. 1.6±0.0 µmol H(2)O(2) Eq/L, 10.3±1.1 vs. 6.9±1.2 µmol H(2)O(2) Eq/L, and 236.4±19.5 vs. 228.2±19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010-12 /pmc/articles/PMC3020342/ /pubmed/21340220 http://dx.doi.org/10.1590/S1807-59322010001200014 Text en Copyright © 2010 Hospital das Clínicas da FMUSP http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Science
Savas, Murat
Yeni, Ercan
Verit, Ayhan
Gulum, Mehmet
Aksoy, Nurten
Ciftci, Halil
Celik, Hakim
Altunkol, Adem
Oncel, Halil
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_full Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_fullStr Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_full_unstemmed Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_short Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_sort acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020342/
https://www.ncbi.nlm.nih.gov/pubmed/21340220
http://dx.doi.org/10.1590/S1807-59322010001200014
work_keys_str_mv AT savasmurat acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT yeniercan acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT veritayhan acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT gulummehmet acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT aksoynurten acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT ciftcihalil acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT celikhakim acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT altunkoladem acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT oncelhalil acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction

Ejemplares similares